ClinicalTrials.gg
Active, not recruitingNCT05293964Updated Nov 29, 2024

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

A Phase 1 interventional study of SIM0270 and Palbociclib in Breast Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
214
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
536th of 1,520
214 · median 120
Started
2022
with 179 others
Phase 1
171 of 1,930
61 open now
Primary completion
2024-12
later than 124 of 1,064 live
Registered
873rd of 1,930
by date

Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 536th largest by enrollment of the 1,520 interventional ones that give a count, is one of 180 that started in 2022, is one of 171 in phase 1, reaches primary completion later than 124 of the 1,064 other live ones, and was the 873rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

863 more — sign in →

All 868 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,930 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, pharmacokinetic (PK) and anti-tumor efficacy of SIM0270 and SIM0270 in combination with palbociclib or everolimus in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.

Read the detailed description

The study is comprised of two parts: Phase Ia and Phase Ib. Phase Ia includes dose-escalating stage and dose expansion stageof SIM0270 monotherapy to determine the MTD/ RP2D and the preliminary safety and efficacy of SIM0270; Phase Ib includes 2 arms, armA: dose escalation and dose expansion of SIM0270 in combination with palbociclib; armB: dose escalation and dose expansion of SIM0270 in combination with palbociclib everolimus; phase Ib is designed to determine the MTD/RP2D and the preliminary safety and efficacy of SIM0270 in combination with palbociclib or everolimus.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

key Inclusion Criteria:

  1. voluntary participation in clinical trials and signature of .
  2. age ≥ 18 years, male or female.
  3. or cytologically confirmed /locally advanced ER-positive, negative breast cancer subjects.
  4. previous treatment meets the criteria of the protocol defined.
  5. score of 0 or 1 .
  6. at least one that meets RECISTv1.1 criteria. Osteolytic lesions can be included in the Ia dose-escalating .
  7. expected survival ≥ 12 weeks.
  8. Adequate organ and bone marrow function.
  9. Women of must have a negative serum pregnancy test within 7 days prior to the first dose.
  10. women; Premenopausal or perimenopausal female subjects met protocol requirements.

key Exclusion Criteria:

  1. Documented medical history or ongoing gastrointestinal disease or other malabsorption that may affect the absorption of oral study drug.
  2. Participated in other clinical trials of drugs or investigational devices within 28 days before the first medication; or received chemotherapy, targeted therapy, immunotherapy and clinical trial medication and other anti-tumor treatment within 4 days or 5 half-lives of the first medication (whichever is shorter), or received radiotherapy, endocrine drugs or Chinese patent medicines with anti-tumor indications 2 weeks before the first medication;
  3. The toxicity of previous anti-tumor treatment has not recovered to grade 0 or 1 (alopecia, chemotherapy-induced peripheral neurotoxicity ≤ grade 2 can be included).
  4. Major surgical surgery (except ) or incomplete healing of the surgical incision 4 times before the first study drug treatment;
  5. Known other malignant tumors within 2 years before enrollment (except treated basal cell carcinoma, scaly cell carcinoma and/or radical carcinoma in situ);
  6. confirmed by MRI or known cytology of CSF, or cranial Increased internal pressure or with unstable central nervous symptoms (within 2 weeks prior to initial medication Treatment with any craniotropic, glucocorticokinin, or anticonvulsant);
  7. Previous history of interstitial lung disease, drug-induced interstitial lung disease, symptomatic interstitial lung disease or any evidence of active pneumonia on chest CT scan 4 before the first study drug treatment;
  8. known to interfere with the test requirements of mental illness or drug abuse disease.
  9. History of HIV infection, or active bacterial or fungal infection requiring systemic treatment .
  10. presence of active syphilis infection.
  11. Subjects with known active virus (HBV) or virus (HCV) infection with abnormal liver function.
  12. History of cardiovascular disease.
  13. History of serious allergic reactions to the study drugs or used in the protocol.
  14. Women who are pregnant or lactating.
  15. Prior use of SERD oral medications.
  16. Subjects who use drugs or herbal supplements known to be moderate/strong inhibitors of 2 Weeks before the first dose.Or Subjects who use drugs or herbal supplements known to be moderate/strong inducers of CYP3A 4 weeks before the first dose.
  17. Other conditions that the investigator considers unsuitable for this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    SIM0270

    Phase Ia SIM0270 monotherapy dose escalation and expansion

    Drug: SIM0270

  • Experimental
    SIM0270+palbociclib

    Phase Ib SIM0270 with palbociclib dose escalation and expansion

    Drug: SIM0270 · Drug: Palbociclib

  • Experimental
    SIM0270+everolimus

    Phase Ib SIM0270 with everolimus dose escalation and expansion

    Drug: SIM0270 · Drug: everolimus

Interventions

  • SIM0270 is an oral, selective estrogen receptor degrader (SERD)

    Also known as: SCR6852

  • palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6

  • Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose

    Dose Escalation: Maximum Tolerated Dose (MTD) of SIM0270 When Administered as a Single Agent or in Combination with Palbociclib or Everolimus

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. recommended phase 2 Dose

    Dose Escalation: recommended phase 2 Dose (RP2D) of SIM0270 When Administered as a Single Agent or in Combination with Palbociclib or Everolimus

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Dose-Limiting Toxicities

    Dose Escalation: Number of Participants with Dose-Limiting Toxicities When SIM0270 is Administered as a Single Agent or in Combination with Palbociclib or Everolimus

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Adverse event

    Number of Participants with Adverse Events by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)

    Time frame: From Baseline until 30 days after the last dose of study treatment

  2. Peak Plasma Concentration (Cmax) of SIM0270 as monotherapy or combination with palbociclib or everolimus

    Peak Plasma Concentration (Cmax)

    Time frame: At the end of Cycle 4 (each cycle is 28 days)

  3. Time of Peak Plasma Concentration (Tmax) of SIM0270 as monotherapy or combination with palbociclib or everolimus

    Time of Peak Plasma Concentration (Tmax)

    Time frame: At the end of Cycle 4 (each cycle is 28 days)

  4. Area under the plasma concentration versus time curve (AUC) of SIM0270 as monotherapy or combination with palbociclib or everolimus

    Area under the plasma concentration versus time curve (AUC)

    Time frame: At the end of Cycle 4 (each cycle is 28 days)

  5. clinical benefit rate

    Antitumour activity by evaluation of clinical benefit rate assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)

    Time frame: through study completion, an average of 1 year

  6. disease control rate

    Antitumour activity by evaluation of disease control rate assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)

    Time frame: through study completion, an average of 1 year

  7. duration of response

    Antitumour activity by evaluation of duration of response assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)

    Time frame: through study completion, an average of 1 year

  8. progression free survival

    Antitumour activity by evaluation of progression free survival assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)

    Time frame: From date of C1D1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  9. time to progression

    Antitumour activity by evaluation of time to progression assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)

    Time frame: From date of C1D1 until the date of first documented progression, assessed up to100 months

  10. time to response

    Antitumour activity by evaluation of time to response assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)

    Time frame: through study completion, an average of 1 year

  11. overall survival

    Antitumour activity by evaluation of overall survival assessments

    Time frame: From date of C1D1 until the date of death from any cause, assessed up to 100 months

  12. overall response rate

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in breast cancer (RECIST 1.1)

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — the plan to make individual participant data (IPD) available to other researchers is not decided yet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2024, 31 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 31 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 24, 2022
StartActual
May 18, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Sep 8, 2025
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05293964
Collaborators
Nanjing Zaiming Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 24, 2022
Start date
May 18, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Sep 8, 2025 (estimated)
Last update
Nov 29, 2024

Study contacts

Jiong Wu, phD
principal investigator · chief physician

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SIM0270

Start the discussion